Glaxo Drug May Help Shrink Metastatic Brain Tumors
Study results show the new oral drug Tykerb from GlaxoSmithKline, combined with chemotherapy, may shrink metastatic brain tumors.
The data presented Sunday at a breast cancer conference in San Antonio indicate that 20 percent of patients whose cancer had spread to their brain saw their brain tumors cut more than in half, and 37 percent of patients had them shrink 20 percent or more.
Experts say very few drugs have been shown to be able to get at brain metastases in patients with a certain type of advanced breast cancer.
The study, which Glaxo paid for, was relatively small, and investigators say larger tests are needed.